Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PROPHYLACTIC TREATMENT WITH LORATADINE VERSUS CROMOLYN SODIUM IN CHILDREN WITH MILD-TO-MODERATE PERENNIAL ALLERGIC-ASTHMA
Autore:
MENARDO JL; WESSEL F; COUGNARD J; CZARLEWSKI W;
Indirizzi:
SCHERING PLOUGH CORP,DEPT MED,92 RUE BAUDIN F-92307 LEVALLOIS PERRET FRANCE SCHERING PLOUGH CORP,DEPT MED F-92307 LEVALLOIS PERRET FRANCE
Titolo Testata:
Current therapeutic research
fascicolo: 8, volume: 59, anno: 1998,
pagine: 567 - 578
SICI:
0011-393X(1998)59:8<567:PTWLVC>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
INHIBITORY ACTIVITY; LONG-TERM; KETOTIFEN; TERFENADINE; CROMOGLYCATE; CETIRIZINE; PLACEBO; ANTIHISTAMINES; PREVENTION; ASTEMIZOLE;
Keywords:
LORATADINE; CROMOLYN SODIUM; ALLERGIC ASTHMA; ANTI-H-1; CHILDREN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
46
Recensione:
Indirizzi per estratti:
Citazione:
J.L. Menardo et al., "PROPHYLACTIC TREATMENT WITH LORATADINE VERSUS CROMOLYN SODIUM IN CHILDREN WITH MILD-TO-MODERATE PERENNIAL ALLERGIC-ASTHMA", Current therapeutic research, 59(8), 1998, pp. 567-578

Abstract

Although new antihistamines exert additional antiallergic properties besides blocking histamine(1) (H-1) receptors, their potential for prophylactic treatment of asthma has not been thoroughly investigated. This study compared the efficacy and tolerability of loratadine with those of cromolyn sodium, the nonsteroidal prophylactic treatment of choice for mild-to-moderate childhood perennial allergic asthma. A total of 122 children (mean age, 10 +/- 2 years) with mild-to-moderate perennial allergic asthma were enrolled in a multicenter, double-masked, double-dummy, randomized parallel-group study. They received either cromolyn sodium (two 5-mg puffs four times daily) or loratadine (10 mg if body weight was less than or equal to 30 kg or 20 mg if >30 kg) for 8 weeks. The efficacy was assessed by wheezing, cough, and asthma symptomscores, overall assessment of asthma severity, peak expiratory flow recordings, forced expiratory volume in I second (FEV1) measurements, and use of inhaled beta(2)-agonists. Tolerability was assessed by recording possible adverse reactions and blood test results. Wheezing decreased significantly in patients in both groups from day 0 to day 56; cough decreased significantly only in the loratadine group. Similarly, asthma score decreased significantly only in the loratadine group. Physicians and parents reported a highly significant reduction in asthma severity and in the number of patients using beta(2)-agonists in both groups. Peak-flow and FEV1 values remained constant in both groups throughout the study. No statistically significant difference was observedbetween the treatment groups in any variable. In addition, tolerability was similar and satisfactory for both groups. Results of this studysuggest that loratadine could be an alternative to cromolyn sodium inthe treatment of mild-to-moderate childhood perennial allergic asthma.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/09/18 alle ore 08:12:51